Browse the evidence

Semaglutide has a favorable safety profile across diverse patient populations and treatment durations.

Clinicians can consider semaglutide as a safe option for managing type 2 diabetes and obesity.

Females tended to lose more weight (Mean = 9.75) than males (Mean = 8.41).

Practitioners may consider gender differences when designing weight-loss interventions.

Diabetes management is being transformed by continuous glucose monitoring (CGM) systems and closed-loop insulin delivery.

Healthcare providers should adopt CGM systems and closed-loop delivery for improved diabetes management.

Effects on gastric emptying appeared additive when BI 1820237 was combined with low-dose liraglutide.

Combining BI 1820237 with liraglutide may enhance effects on gastric emptying, which could be relevant for treatment strategies.

The combination of long-acting PYY analogs with a GLP-1 receptor agonist resulted in superior blood glucose lowering and greater body weight loss compared to GLP-1 alone.

Suggests a potential strategy for enhanced diabetes and obesity treatment.

Co-agonism of the glucagon and GLP-1 receptors improves glycemia in people with diabetes and obesity.

Practitioners may consider glucagon and GLP-1 receptor co-agonists as a treatment option for improving glycemia.

Continuous glucose monitoring can provide benefits when initiating GLP-1RA treatment.

Implementing continuous glucose monitoring can enhance the safety and effectiveness of GLP-1RA therapy.

The gut is a promising target for therapeutic interventions to achieve significant weight loss.

Practitioners should consider gut-targeted therapies as viable options for obesity treatment.

The quality of life after ESG was rated as good or better by 82% of patients.

Practitioners can expect significant improvements in patient quality of life following ESG.

GLP-1 receptor agonists have better side-effect profiles than other weight management treatments.

Healthcare providers may prefer GLP-1 receptor agonists for patients due to their favorable side-effect profiles.

An oral formulation of semaglutide (7 or 14 mg once daily) has been approved by the FDA for the treatment of type 2 diabetes.

Practitioners can consider the oral formulation of semaglutide as an option for managing type 2 diabetes.

Dual and triple agonists show effectiveness on validated surrogate NAFLD biomarkers.

There is potential for dual and triple agonists to be effective in treating NAFLD, warranting further investigation.

GIP receptor agonism and antagonism both lead to weight reduction.

Both GIP receptor agonists and antagonists could be explored for obesity treatment strategies.

The macrovascular benefits of GLP-1 receptor agonists should be prioritized over potential microvascular progression of DR.

Healthcare providers should weigh the cardiovascular benefits of GLP-1 receptor agonists against the risks of worsening DR.

Semaglutide treatment following catheter ablation for atrial fibrillation is associated with a lower rate of atrial arrhythmia recurrence over 12 months (hazard ratio, 0.68; P =0.030).

Practitioners may consider semaglutide as a therapeutic option to reduce atrial arrhythmia recurrence post-ablation.

In men, a 14.4% ILI-associated increase in total testosterone at year 1 mediated increases in weight (189 g; 95% CI, 65-317) and waist circumference (0.135 cm; 95% CI, 0.19-0.248) at year 4.

Practitioners should consider the role of testosterone in managing weight and waist circumference in men with type 2 diabetes.

In women, a 21.8% decrease in bioavailable testosterone at year 1 mediated decreases in whole-body fat mass (-164; 95% CI, -326 to -29.3), whole-body lean mass (-115 g; 95% CI, -203.4 to -40), and trunk lean mass (-97.2 g; 95% CI, -156 to -45.5) at year 4.

Practitioners should consider the role of bioavailable testosterone in managing body composition in women with type 2 diabetes.

The study revealed sex-specific mediating effects of sex hormones due to weight loss from intensive lifestyle intervention on body composition changes in people with type 2 diabetes.

Practitioners should tailor weight loss recommendations based on sex differences in hormone responses.

49% of patients receiving semaglutide treatment had a full stomach compared to 18% of matched controls.

Clinicians should be aware of the increased risk of full stomach in patients on semaglutide during pre-operative assessments.

Semaglutide improved hemoglobin A1c levels and reduced glycemic variability without increasing hypoglycemia.

Semaglutide may enhance glycemic control in type 1 diabetes patients.

Tirzepatide has potential cardiovascular benefits.

Practitioners should consider the cardiovascular implications when prescribing TZP.

Significant improvements were observed across quality-of-life scores.

Incorporating exercise and nutrition can enhance the quality of life for breast cancer patients.

Incretin mimetics have a positive impact on related comorbidities, such as sleep apnea and heart failure.

Practitioners should be aware of the broader health benefits of incretin mimetics beyond glucose control.

Patients may benefit from education on proper drug administration, anticipated adverse effects, and nutrition considerations with treatment.

Educating patients on these aspects can improve treatment adherence and outcomes.